ArticleNature communications2020
Escape mutations circumvent a tradeoff between resistance to a beta-lactam and resistance to a beta-lactamase inhibitor.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance.Journal of microbiology (Seoul, Korea) · 2026Review
- Effect of Mutations on the Evolution of Extended Spectrum β-lactamases (ESBL).The protein journal · 2025Review
- Drug resistant Klebsiella pneumoniae from patients and hospital effluent: a correlation?BMC microbiology · 2025Article
- Metabolic state-driven nutrient-based approach to combat bacterial antibiotic resistance.npj antimicrobials and resistance · 2025Review
- Reversible Evolution of Ceftazidime-Avibactam Resistance Driven byInfection and drug resistance · 2025Article
- In Silico Study of the Potential of Brazilein Sappan Wood as a Beta-Lactamase Inhibitor against Extended-Spectrum Beta-Lactamase-Encoding Genes.The Malaysian journal of medical sciences : MJMS · 2024Article
- Dynamic Effect of β-Lactam Antibiotic Inactivation Due to the Inter- and Intraspecies Interaction of Drug-Resistant Microbes.ACS biomaterials science & engineering · 2024Article
- Extended-spectrum β-lactamase- producing gram-negative bacterial infections in severely ill COVID-19 patients admitted in a national referral hospital, Kenya.Annals of clinical microbiology and antimicrobials · 2023Article
- Article
- Re-Imagining Drug Discovery using Mass Spectrometry.Israel journal of chemistry · 2023Article
- Resistance to aztreonam-avibactam due to a mutation of SHV-12 in Enterobacter.Annals of clinical microbiology and antimicrobials · 2023Article
- Review
- Reporting off-target effects of recombinant engineering using the pORTMAGE system.Journal of microbiological methods · 2023Article
- Host-parasite coevolution promotes innovation through deformations in fitness landscapes.eLife · 2022Article
- A Phage Foundry Framework to Systematically Develop Viral Countermeasures to Combat Antibiotic-Resistant Bacterial Pathogens.iScience · 2022Review
- Environmental selection and epistasis in an empirical phenotype-environment-fitness landscape.Nature ecology & evolution · 2022Article
- Three new inhibitors of class A β-lactamases evaluated by molecular docking and dynamics simulations methods: relebactam, enmetazobactam, and QPX7728.Journal of molecular modeling · 2022Article
- Resistance to aztreonam-avibactam due to CTX-M-15 in the presence of penicillin-binding protein 3 with extra amino acids inFrontiers in microbiology · 2022Article
- Antibiotic Resistance in Pseudomonas.Advances in experimental medicine and biology · 2022Article
- Synergistic evaluation of Moringa oleifera extract and ß-lactam antibiotic to restore the susceptibility of methicillin-resistant Staphylococcus aureus.Molecular biology reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
Beta-lactamase inhibitors are increasingly used to counteract antibiotic resistance mediated by beta-lactamase enzymes. These inhibitors compete with the beta-lactam antibiotic for the same binding site on the beta-lactamase, thus generating an evolutionary tradeoff: mutations that increase the enzyme's beta-lactamase activity tend to increase also its susceptibility to the inhibitor. Here, we investigate how common and accessible are mutants that escape this adaptive tradeoff. Screening a deep mutant library of the bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.